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Abstract
von Hippel–Lindau (VHL) disease is a hereditary cancer syndrome caused by inherited mutations that inactivate the VHL tumour 
suppressor gene. The VHL locus encodes pVHL, whose best studied function is to bind to and down-regulate the hypoxia-inducible 
factor (HIF) family of oxygen-dependent transcription factors. Early efforts have established the fundamental role of HIF in VHL-defective
tumorigenesis and in particular renal cell carcinoma. However, recent findings have revealed an alternate side to the story, the HIF-
independent tumour suppressor functions of pVHL. These include pVHL’s ability to regulate apoptosis and senescence as well as its role
in the maintenance of primary cilium and orchestrating the deposition of the extracellular matrix. To what extent these HIF-dependent
and HIF-independent functions cooperate in VHL-defective tumorigenesis remains to be determined.
Keywords: von Hippel–Lindau • pVHL • HIF • hypoxia-inducible factor • tumorigenesis • renal cell carcinoma •
pheochromocytoma • senescence • cilia
J. Cell. Mol. Med. Vol 15, No 2, 2011 pp. 187-195
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2010.01238.x
Guest Edior: M. Ivan & W.Y. Kim
Introduction
VHL disease was first described in the medical literature in the late
19th century by the British surgeon and ophthalmologist, Treacher
Collins, who reported on the occurrence of bilateral retinal 
haemangiomas in a pair of siblings [1]. Subsequent observations
by Eugen von Hippel and Arvid Lindau linked the occurrence of
retinal haemangiomas to central nervous system haemangioblas-
tomas [2]. The term VHL disease was later coined by the neuro-
surgeon Harvey Cushing.
Patients with VHL disease are at increased risk for a variety of
cancers, including renal cell carcinoma (RCC) of the clear cell his-
tology, central nervous system haemangioblastomas (especially
of the cerebellum and spinal cord), retinal haemangiomas and
pheochromocytomas [2]. Other manifestations include visceral
cysts of the kidney and pancreas, pancreatic islet cell tumours and
epididymal or broad ligament papillary cystadenomas (in men and
women, respectively) (Fig. 1). In affected families, cancer risk is
transmitted in an autosomal-dominant manner.
Genetic linkage studies performed in the 1980s indicated that
the VHL gene (VHL) resides on chromosome 3p25, which is a
region of the genome that is commonly deleted in sporadic kidney
cancers [3]. This information was used to successfully isolate the
VHL gene in 1993 [4]. Although RCC and haemangioblastomas
are the leading cause of death in patients with VHL disease,  
retinal haemangiomas have the potential to cause significant
 morbidity (blindness) because of their association with posterior
retinal detachment. Over the past century, studies focusing on the
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structure and function of the VHL tumour suppressor gene and its
protein product, pVHL, have been highly informative with respect
to the pathogenesis of clear cell renal carcinoma as well as the
molecular mechanisms of oxygen sensing.
The VHL protein, pVHL
The VHL gene consists of three exons and is ubiquitously
expressed. Translation of the VHL mRNA gives rise to two differ-
ent protein products secondary to the presence of two distinct 
in-frame ATG codons (codon 1 and 54), which can both serve as
translational initiation sites [5–7]. In most biochemical and func-
tional assays, the two proteins (pVHL30 and pVHL19) behave 
similarly and unless otherwise noted are referred to generically as
pVHL. pVHL is primarily a cytoplasmic protein but can also be
found elsewhere, including the nucleus, the mitochondria and in
association with the endoplasmic reticulum [8]. In fact, pVHL
shuttles back and forth between the nucleus and the cytoplasm,
and pVHL cannot suppress tumour growth when artificially
restrained from doing so [9, 10].
HIF-dependent pVHL functions
Many functions have been attributed to pVHL; however, the one
best characterized and most clearly linked to the development of
pVHL-defective tumours, is targeting of the hypoxia-inducible fac-
tor (HIF) transcription factor for proteolytic degradation (Fig. 2).
HIF is a heterodimeric transcription factor consisting of an unsta-
ble  subunit and a stable  subunit. Three HIF genes (HIF1,
HIF2 and HIF3) have been identified in the human genome [11].
Both HIF1 and HIF2 have two transcriptional activation
domains, the N-terminal transactivation domain (NTAD) and the 
C-terminal transactivation domain (CTAD), which activate target
genes upon DNA binding [12].
HIF1 and HIF2 do not appear to be fully redundant in func-
tion. Although germline knock-out of HIF1 and HIF2 results in
embryonic lethality the timing and cause of death appear to dif-
fer [13–15]. Moreover, post-natal inactivation of HIF1 and
HIF2 leads to differing phenotypes as well [16]. Finally, the
global gene expression changes induced by HIF1 and HIF2 show
that they produce overlapping yet distinct gene expression pro-
files in both cells and in mice [17–21]. The role of HIF3, which
possesses a NTAD but lacks a CTAD, in transcriptional regulation
is less well defined, and some HIF3 splice variants appear 
to inhibit HIF-dependent transcriptional activation in vitro and 
in vivo [22–25].
Hydroxylation of HIF
When oxygen levels are high (normoxia), HIF subunits are enzy-
matically hydroxylated on one or both prolyl residues that reside
near the NTAD by members of the oxygen- and 2-oxoglutarate-
dependent prolyl hyroxylase (PHD) family [26–29]. There are at
least three PHDs identified to date: PHD1 (EGLN2), PHD2 (EGLN1)
and PHD3 (EGLN3) [30]. Although PHD2 is believed to be the 
primary hydroxylase for both HIF1 and HIF2, other studies 
indicate that PHD3 may be mainly responsible for HIF2 hydrox-
ylation [31, 32]. Hydroxylation of one or both proline residues
within HIF1 and HIF2 creates a high affinity pVHL binding site.
pVHL is part of a multi-subunit ubiquitin ligase complex com-
posed of elongin-B, elongin-C, Cullin-2 and ring-box 1 (Rbx1)
[33]. pVHL serves as a substrate recognition component that
brings the ubiquitin conjugating machinery into proximity of its
substrate, HIF subunits, and leads to HIF polyubiquitylation and
destruction [26, 27, 34, 35].
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Fig. 1 Clinical manifestations of VHL dis-
ease. Summary of the spectrum of benign
and malignant tumours seen in association
with VHL disease. Special notes: Retinal
haemangiomas are found in up to 70% of
VHL patients who survive to age 60 years.
Haemangioblastomas are the most common
lesions associated with VHL disease and are
found most frequently in the cerebellum and
spinal cord. Lung cysts appear to be rare,
occurring in 1% of VHL patients.
Pancreatic neuroendocrine tumours are
 relatively rare (9%) and are typically non-
functional. The incidence of broad ligament
papillary cystadenomas in women is not
known secondary to their asymptomatic
nature.
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When oxygen availability is limiting (hypoxia), the PHDs are
enzymatically inactive, HIF is therefore not hydroxylated, and
does not interact with the pVHL complex. HIF subunits therefore
accumulate, translocate to the nucleus, heterodimerize with HIF
(also called ARNT [aryl hydrocarbon nuclear translocator] and
activate transcription of numerous target genes involved in cell
proliferation, angiogenesis, glucose metabolism, apoptosis and
other cellular processes. Similarly, in the setting of VHL inactiva-
tion, although HIF subunits are prolyl hydroxylated, they are not
degraded, and similar to hypoxia, are free to transactivate HIF tar-
get genes (Fig. 2).
Soon after the discovery that HIF subunits were prolyl
hydroxylated, they were noted to be post-translationally hydroxy-
lated in an oxygen-dependent manner on a conserved asparaginyl
residue located in the CTAD by the asparaginyl hydroxylase,
 factor-inhibiting HIF (FIH1) (Fig. 2) [36, 37]. Asparaginyl hydroxy-
lation of HIF prevents recruitment of the transcriptional co-
 activators p300 and CREB (cAMP response element binding
 protein) binding protein (CBP), and disrupts HIF-mediated trans-
activation [37]. In contrast to the PHD family, FIH1 remains active
even under conditions of moderate hypoxia suggesting that in this
setting it may act as a secondary mechanism to inhibit HIF tran-
scriptional activity [38]. Interestingly, the CTAD of HIF2 appears
to be relatively more resistant to inhibition of FIH1 under normoxia
than the HIF1 CTAD [39].
HIF is a key mediator of VHL defective tumorigenesis
Given the early age of onset of VHL-associated tumours such as
retinal haemangiomas, VHL inactivation is likely to be sufficient for
their development. Other VHL associated tumours, such as RCC
however, have a longer latency and more variable penetrance, sug-
gesting that VHL loss alone is insufficient for their tumorigenesis.
Nonetheless, it is clear that VHL inactivation is necessary for their
development and that HIF dysregulation plays an important role in
this process. Indeed there are several lines of evidence that impli-
cate HIF, and in particular HIF2, as playing an active role in
VHL–/– renal cell carcinogenesis. First and foremost, RCC-associ-
ated pVHL mutants are invariably defective with respect to HIF
polyubiquitination and therefore all VHL defective RCCs produce
either HIF1 and HIF2 or solely HIF2 [2, 40–42]. This would
suggest that there may be selective pressure to maintain HIF2
expression, but not HIF1. Indeed, whole exosome sequencing
from sporadic RCCs detected a significant, but low frequency of
truncating mutations in HIF1 suggesting that in RCC it may func-
tion as a tumour suppressor [43]. Second, an apparent switch
from HIF1 to HIF2 expression occurs in preneoplastic lesions
arising in human VHL/ kidneys in association with increasing
dysplasia and cellular atypia [42]. Furthermore, HIF2 activation
in mice appears to induce gene expression changes similar to
mice with VHL inactivation, whereas HIF1 activation does so to a
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Fig. 2 pVHL controls HIF via oxygen-sensitive
hydroxylation. HIF subunits have both an NTAD
and a CTAD transactivation domain. When O2
levels are high, HIF is hydroxylated on one or
both conserved prolyl (Pro) residues located
within the NTAD by the oxygen-dependent
PHD2. This prolyl hydroxylation event generates
a high affinity binding site for the pVHL E3 ubiq-
uitin ligase complex composed of Cullin 2
(Cul2), Elongin B (EloB), Elongin C (EloC) and
Rbx1. The pVHL complex polyubiquitinates
HIF, leading to its destruction by the protea-
some. When O2 levels are intermediate, HIF is
hydroxylated by factor inhibiting HIF (FIH1) at a
conserved asparaginyl (Asn) residue located in
the CTAD, inhibiting HIF’s interaction with the
transcriptional co-activators p300/CBP. When O2
levels are low, HIF subunits are stabilized, able
to heterodimerize with the constitutively stable
HIF, interact with p300/CBP and promote the
transcription of downstream target genes. In
cells lacking VHL, PHD2 and FIH1 remain active
but HIF subunits are not polyubquitinated and
therefore allowed to accumulate.
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much less significant degree [19]. Finally, in VHL–/– RCC cell lines,
HIF2, but not HIF1, appears to be necessary and sufficient for
tumour growth [44–47].
Germline inactivation of Vhl in mice is embryonic lethal and
whereas Vhl/ mice do not have a cancer prone phenotype, they
do develop liver haemangiomas as a result of loss of the remain-
ing wild-type Vhl allele [48]. Similarly, conditional inactivation of
Vhl in hepatocytes results in vascular liver lesions accompanied
by hepatic steatosis [48]. HIF expression is both necessary and
sufficient to recapitulate the hepatic phenotypes seen in mice as
inactivation of Anrt or dual activation of HIF1 and HIF2 were
able to abrogate or induce the hepatic phenotypes seen in Vhl
loss, respectively [19, 49]. Unfortunately at this time there are no
autochthonous mouse models of Vhl–/– RCC that can be used to
investigate HIF’s role in that setting.
Several clues exist as to why HIF2 may be more oncogenic
than HIF1. First, HIF2 is less sensitive than HIF1 to the inhibi-
tion by FIH-1 and is therefore more transcriptionally active under
normoxia [50]. Second, HIF1 more than HIF2, remains suscep-
tible to proteasomal degradation in VHL–/– cell lines [19]. Third,
HIF2 appears to cooperate with MYC to activate MYC transcrip-
tional targets whereas HIF1 antagonizes MYC transcriptional
activation [51]. Interestingly, a recent genome-wide analysis of
copy number alterations noted that a region of chromosome 8q
encoding MYC is often amplified in both sporadic and VHL disease
associated tumours [52]. Whether or not HIF2 activation in 
concert with MYC overexpression cooperate in vivo has yet to 
be determined.
HIF responsive genes
More than 100 direct HIF-responsive genes have been described
with a number of these genes active in carcinogenesis (Fig. 3)
[53]. These include genes that encode proteins responsible for cell
proliferation (transforming growth factor [TGF] and epidermal
growth factor receptor [EGFR]); angiogenesis (vascular endothe-
lial growth factor [VEGF], platelet-derived growth factor B [PDGF-
B] and interleukin-8 [IL-8]); glucose uptake and metabolism (glu-
cose transporter 1 [GLUT1], 6-phosphofructokinase 1 [PFK1]);
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Fig. 3 pVHL inactivation mediates both HIF-dependent and HIF-independent pathways. HIF-responsive gene products play important roles in tumorigenesis.
EGFR and TGF promote cell proliferation and survival. VEGF, PDGF and connective tissue growth factor (CTGF) stimulate angiogenesis. Some proteins
encoded by HIF-targeted gene products are responsible for regulating glucose uptake and metabolism, such as GLUT1, 6-PFK and pyruvate dehydrogenase
kinase (PDK). CXCR4 and its ligand SDF1 stimulate chemotaxis and may also contribute to tumour cell invasion and metastases. MMP1 and lysyl oxidase
(encoded by LOX) are implicated in ECM breakdown and tumour cell invasion/migration. Finally, dysregulation of TWIST (TWIST1 and TWIST2) and 
activation of HGFR (encoded by c-MET) are involved in EMT. pVHL has a number of HIF-independent functions as well. pVHL interacts with MDM2 and sup-
presses its ability to ubiqutinate p53, resulting in p53 accumulation and apoptosis. It can also act as an adaptor to bind CK2, which inactivates the NF-kB
agonist CARD9, leads to inhibition of NF-kB signalling and overall inhibits cell survival. pVHL also down-regulates atypical protein kinase C (aPKC), which
secondarily results in decreased levels of JUNB (an antagonist of JUN) thus permitting JUN-dependent neuronal apoptosis. Acute pVHL loss causes a
senescent-like phenotype. It appears that pVHL increases p400 activity, which results in inactivation (hypophosphorylation) of the retinoblastoma protein
(pRb) and prevents senescence. pVHL also interacts with collagen IV (Col IV), Kinesin 2 and fibronectin to ensure proper ECM deposition. Finally, pVHL
plays an important role in primary cilium function by promoting microtubule stabilization and binding with aPKC and the polarity proteins Par3 and Par6.
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and chemotaxis (stromal cell-derived factor [SDF1] and its recep-
tor C-X-C chemokine receptor 4 [CXCR4]). A number of gene
products that are expected to have effects on the tumour microen-
vironment such as extracellular matrix (ECM) formation and
turnover (membrane type 1 matrix metalloproteinase [MMP1] and
lysyl oxidase [LOX]) are HIF responsive. Moreover, epithelial to
mesenchymal transition (EMT) related genes (Twist [TWIST1 and
TWIST2] and hepatocyte growth factor receptor [HGFR]) are
known HIF target genes as well [53].
HIF-independent pVHL functions
Recent evidence has accrued to indicate that pVHL has functions
other than regulation of HIF-related pathways. The majority of
these alternate functions have been discovered through biochem-
ical interactions. However, gene expression studies also support
the notion that there are HIF-independent gene expression
changes induced by VHL loss [54, 55]. To what extent the HIF-
independent functions of pVHL cooperate with HIF dysregulation
in VHL defective tumorigenesis remains to be delineated.
Regulation of apoptosis
RCCs are notable for their insensitivity to conventional cytotoxic
chemotherapies. The efficacy of chemotherapy is tightly linked to
p53-mediated apoptosis [56]. However, most RCCs do not appear
to harbour p53 mutations or loss suggesting either functional
modulation of p53 activity or activation of alternative anti-apop-
totic pathways [57, 58]. Both HIF and pVHL appear to be able to
influence p53 function. Previous reports have shown that HIF can
directly bind to and modulate p53 activity [59–61]. In addition,
pVHL is able to regulate p53 function in a HIF-independent man-
ner through suppression of MDM2-mediated ubiquitination and
nuclear export resulting in an increase in its transcriptional activ-
ity [62]. Therefore pVHL loss appears to result in p53 inactivation
by both HIF-dependent and HIF-independent effects.
The nuclear factor B (NF-B) pathway can mediate resistance
to chemotherapy-induced apoptosis as well. pVHL deficient cells
have been noted to have heightened NF-B activity at least par-
tially dependent upon HIF signalling [63–66]. In addition, pVHL
can modulate NF-B activity directly by binding with casein kinase
2 (CK2) and promoting the inhibitory phosphorylation of the NF-
B agonist CARD9 [67]. It seems possible that the ability of pVHL
loss to both activate NF-B and inactivate p53 may contribute to
its profound chemoresistant phenotype.
Although sporadic RCC and haemangioblastomas harbour a
high percentage of VHL mutations, VHL mutations are uncommon
in truly sporadic pheochromocytomas [2, 68]. Indeed, 11% of
apparently sporadic pheochromocytomas (defined by a lack of a
family history or a spectrum of tumours suggestive of VHL dis-
ease) are actually due to occult germline, not sporadic, mutation
of VHL [69]. This peculiarity, along with the knowledge that some
VHL mutations that are associated with the development of
pheochromocytoma (without an increased risk of RCC or haeman-
gioblastoma) retain their ability to downregulate HIF, suggests that
the development of VHL-associated pheochromocytomas is
related to a HIF-independent function of pVHL [70, 71].
Insight into these apparent discrepancies has been recently
elucidated by Kaelin and colleagues. It has been known for some
time that during development there is an excess number of cells
destined to become sympathetic neurons and that these cells’ sur-
vival is dependent upon nerve growth factor (NGF). As NGF
becomes limiting, these cells undergo JUN-dependent apoptosis.
VHL mutations that are linked to pheochromocytoma development
result in the HIF-independent accumulation of JUNB, which is
known to antagonize the pro-apoptotic function of JUN during
NGF withdrawal [72]. Thus, patients inheriting pheochromocy-
toma associated VHL mutations, presumably have an excess num-
ber of sympathetic neurons due to a relative insensitivity to NGF
withdrawal induced apoptosis. However, whether the increased
risk of pheochromocytoma development in patients with VHL dis-
ease is merely a reflection of an increased number of cells suscep-
tible of forming pheochromocytomas or a distinct oncogenic
mechanism associated with these mutations is unclear.
Control of cell senescence
Cellular senescence is the phenomenon of irreversible growth
arrest in response to DNA damage (including shortened telomeres)
but is also an important in vivo tumour suppressor mechanism
[73, 74]. Interestingly, it has been recognized that physiological
oxygenation can extend the replicative lifespan of cells in culture,
which has typically been attributed to a relative decrease in the
amount of oxidative stress [75]. Several reports have now con-
firmed that this phenomenon is at least in part due to stabilization
of HIF [76, 77]. Interestingly, acute pVHL inactivation (with resultant
HIF stabilization) was observed to induce senescence both in vitro
and in vivo [78]. In this setting however, senescence appeared to
be independent of both HIF and p53 function but primarily relied
on activation of the retinoblastoma protein (pRb) and down-
regulation of the SWItch/Sucrose NonFermentable  (SWI2/SNF2)
chromatin remodelling protein, p400. Recent work showing that
induction of senescence by VHL loss is highly dependent upon
oxygenation along with the differences in the senescence assays
examined (i.e. replicative versus oncogene-induced senescence)
may begin to explain the contrasting results [79].
Microtubule stabilization and maintenance 
of the primary cilium
pVHL associates with and is able to stabilize microtubules. This
function of pVHL appears to be independent of its ability to either
down-regulate HIF and its ubiquitin ligase function. Moreover,
pVHL’s ability to stabilize microtubules is lost in VHL mutations
© 2011 The Authors
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that predispose to the development of haemangioblastomas and
pheochromocytomas, but not those associated with the develop-
ment of RCC [80]. The primary cilium is a specialized structure on
the cell surface that serves an antenna of the cell, and regulates
the transduction of both chemical and mechanical signals [81].
The ciliary axoneme is composed of microtubules arranged in nine
peripheral doublets that are templated from the basal body or
mother centriole. Thus microtubule dynamics and formation and
maintenance of the primary cilium are intimately linked.
Preneoplastic renal cysts are a common feature of VHL dis-
ease. Immunohistochemical and laser capture microdissection
studies have demonstrated that the renal tubular epithelial cells
lining these cysts have lost expression of VHL [42, 82, 83]. Other
inherited familial syndromes are characterized by the development
of renal cystic diseases of the kidney (e.g. autosomal dominant
and recessive polycystic kidney disease [ADPKD and ARPKD,
respectively], and Bardet Biedl syndrome) and despite being phe-
notypically diverse and having distinct extrarenal manifestations,
these disorders are intriguingly unified by genetic defects that
converge on the regulation of ciliogenesis and function [84].
pVHL’s affects on microtubule dynamics is negatively regulated
by its phosphorylation by glycogen synthase kinase 3 (GSK-3)
and appears to be HIF-independent, although some studies sug-
gest that HIF dysregulation may play at least a partial role in the
loss of microtubule stability imparted by pVHL inactivation
[85–87]. Interestingly, active GSK-3 itself can promote micro-
tubule stability and cilium maintenance in a pVHL-independent
manner. When GSK-3 is inactive, for example following activa-
tion of the PI3Kinase-Akt pathway, microtubule stability and cilium
maintenance appear to rely on pVHL once again. In keeping with
the notion that GSK-3 and pVHL redundantly maintain primary
cilia, it appears that the combined loss of VHL and PTEN in a
genetically engineered mouse model cooperate to promote renal
and genital tract cysts [88].
It is an apparent paradox that VHL mutants predisposing to
RCC maintain the ability to regulate microtubule dynamics. One
possibility is that the development of renal cysts secondary to loss
of primary cilia on renal tubular cells lack significant malignant
potential. In this scenario, the majority of RCCs associated with
VHL disease would be expected to arise without an antecedent
cystic phase. To some degree, this is in keeping with the observa-
tion that patients with polycystic kidney disease, despite having a
high renal cystic burden are not clearly at a significantly higher
risk for RCC [89].
Regulation of extracellular matrix formation 
and cell – cell adhesion
The ECM, a physical barrier to cancer cell migration and invasion,
can provide survival signals to cancer cells and aide in the main-
tenance of cell polarity in concert with intercellular junctions [90].
pVHL can bind directly to both fibronectin and hydorxylated colla-
gen IV, and interestingly all pVHL mutants studied to date are
defective in this capacity [71, 91]. The inability of VHL deficient
cells to bind ECM components results in ineffective ECM organi-
zation that is not mediated by HIF [92–94]. Moreover, pVHL’s 
ability to orchestrate proper ECM deposition does not require
binding to the other components of the pVHL complex such as
Cullin2 and Elongins B and C and is regulated at least partially by
the post-translational modification of pVHL by the ubiquitin-like
molecule, NEDD8 [95, 96]. Similarly, cell polarity and assembly of
intercellular junctions (i.e. adherens junctions and tight junctions)
are defective in cells lacking VHL in a HIF-independent process
[97]. How an intracellular protein such as pVHL modulates 
the assembly of the extracellular ECM components remains to be
fully elucidated.
pVHL and synthetic lethality
Synthetic lethality occurs when two non-allelic mutations, which
by themselves are not lethal, result in cell death when they exist
simultaneously [98]. Synthetic lethality provides a framework to
discover drugs that might preferentially kill cancer cells harbour-
ing a cancer-relevant gene, yet leave normal cells unharmed. Two
screens have been performed in attempt to target VHL deficient
cells. A cell based small molecule synthetic lethality screen identi-
fied a compound, STF-62247, that selectively induces autophagic
cell death in VHL-deficient RCC cells but not in those expressing
wild-type VHL [99]. In addition, an shRNA screen targeting a
select group of kinases identified and validated that silencing of
CDK6, MET and MAP2K1 (MEK1) preferentially inhibited the
growth of VHL–/– cells compared with their isogenic VHL wild-type
counterparts [100]. Interestingly, in both screens the selective
killing of cells lacking VHL was HIF-independent leaving open the
possibility that therapies targeting these pathways might cooper-
ate with those targeting HIF.
Conclusions
The VHL tumour suppressor gene is mutated or silenced in the
majority of clear cell RCC. Loss of pVHL function results in the
stabilization of HIF and activation of HIF responsive genes. Many
of these gene products have been shown to be oncogenic in the
context of RCC. In recent years, our understanding of pVHL func-
tion has broadened to include several HIF-independent functions
and it seems likely that more will be uncovered. Despite this
broadened understanding of the consequences of VHL loss, the
therapies in clinical use for RCC to date are primarily focused on
dampening of HIF signalling and although effective have not
achieved remarkable results. It will be interesting to determine
whether targeting of HIF-independent pVHL functions either sepa-
rately or in concert with HIF will lead to improved results.
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